

1 **Title**

2 Revisiting the role of swine on the risk of Japanese Encephalitis Virus (JEV) transmission in the  
3 United States: a rapid systematic review of the literature

4

5 **Authors**

6 *Vanessa De Aguiar Veloso, Center for Outcomes Research and Epidemiology, Department for*  
7 *Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State*  
8 *University, Manhattan, KS, USA, veloso@vet.k-state.edu*

9 *Christy J. Hanthorn, Center for Outcomes Research and Epidemiology, Department of*  
10 *Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State*  
11 *University, Manhattan, KS, USA, cjhanthorn@vet.k-state.edu*

12 *Andrea L. Dixon, Center for Outcomes Research and Epidemiology, Department of Diagnostic*  
13 *Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University,*  
14 *Manhattan, KS, USA, aldixon@vet.k-state.edu*

15 *Ana R. S. Oliveira, School of Veterinary Medicine, University of California Davis, Davis, CA,*  
16 *USA, anaoliv@ucdavis.edu*

17 *Stephen Edache, Center for Outcomes Research and Epidemiology, Department of Diagnostic*  
18 *Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University,*  
19 *Manhattan, KS, USA, edache@vet.k-state.edu*

20 *Natalia Cernicchiaro\*, Center for Outcomes Research and Epidemiology, Department of*  
21 *Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State*  
22 *University, Manhattan, KS, USA, ncernic@vet.k-state.edu*

23

24 **Contact information:**

25 \*Corresponding author: ncernic@vet.k-state.edu; Natalia Cernicchiaro, Kansas State University,  
26 College of Veterinary Medicine, Department of Diagnostic Medicine and Pathobiology, Coles  
27 Hall 332, 1620 Denison Ave., Manhattan, KS, 66506

28  
29 **Contributions of the authors**

30 Natalia Cernicchiaro is the guarantor. Study protocol was initially drafted by Vanessa  
31 Veloso (VV), Andrea Dixon (AD), and Natalia Cernicchiaro (NC), and all authors provided  
32 feedback. Vanessa Veloso will conduct the search and deduplication of reference list obtained  
33 with the primary search strategy. Vanessa Veloso and Christy Hanthorn (CH) will perform the  
34 primary relevance screening, where VV will independently perform the relevance screening of  
35 primary database and Madison Evje (ME) will independently perform the relevance screening of  
36 grey literature, and CH will serve as second reviewers for VV, and VV will serve as second  
37 reviewer for ME (resolving conflicts, and checking excluded and unclear references). Note that  
38 VV and ME will not perform the relevance screening in duplicate, but concurrently (VV will  
39 screen the primary database, and ME will perform hand search and grey literature search and  
40 screening). Vanessa Veloso and CH will independently, and concurrently, conduct the data  
41 extraction (i.e., data extraction will be performed in duplicate). Natalia Cernicchiaro will conduct  
42 the risk of bias assessment. Vanessa Veloso will conduct identification and characterization of  
43 knowledge gaps, data synthesis, and manuscript preparation. Vanessa Veloso, CH, NC, and AD  
44 will identify, develop and/or modify all necessary tools for this rapid review (i.e., relevance  
45 screening tool, data extraction tool, risk of bias tool, and knowledge gap identification tool). All  
46 authors will read and provide feedback on the original and subsequent versions of the

47 manuscript. A final version of the manuscript will be submitted for publication after approval of  
48 all study contributors.

49

#### 50 **Sponsor, support & funding sources**

51 Financial support was provided by the Swine Health Information Center (SHIC), and the  
52 College of Veterinary Medicine at Kansas State University. Sponsors did not have any role in the  
53 design or implementation of the study. Non-financial support and collaboration were provided by  
54 USDA-NBAF FABADRU (Drs. Chad Mire, Leela Noronha and Dana Mitzel) and USDA  
55 APHIS (Dr. Vienna Brown).

56

#### 57 **Background**

58 Japanese Encephalitis (JE) is an emerging, zoonotic disease transmitted primarily by  
59 *Culex* species mosquitoes (particularly *Culex tritaeniorhynchus*) carrying the flavivirus Japanese  
60 encephalitis virus (JEV). Japanese encephalitis virus maintains its life cycle between mosquitoes  
61 and vertebrate hosts, primarily pigs and wading birds (Le Flohic et al., 2013). In humans, JEV  
62 infection causes inflammation of the brain (encephalitis) that can cause fever, headache,  
63 respiratory distress, gastrointestinal pain, confusion, seizures, and, in some cases, death (Fischer  
64 et al., 2012; Hills et al., 2014). The global incidence of JE is uncertain. Effectivity and quality of  
65 JE surveillance in endemic countries vary (Jayatilleke et al. 2020), as does availability of  
66 diagnostic testing throughout the world. In 2006, the WHO published a position paper on JE  
67 vaccines reporting an annual estimation of at least 50,000 new JE cases among those living in  
68 countries considered endemic. Campbell et al. (2011) updated prior estimations and predicted a  
69 global incidence of JE cases to be nearly 67,900 per year. Most recently, Quan et al. (2020)

70 reported a global estimation of JE incidence of approximately 100,000 per year. Among all  
71 clinical cases, children under the age of 10 comprise the majority affected (WHO, 2006).  
72 Whereas less than 1% of the cases are accompanied by symptoms, 30% of the symptomatic cases  
73 are fatal (Campbell et al., 2011). Furthermore, JE is an untreatable and incurable disease that,  
74 once introduced in a community, can lead to devastating economic and health impacts.

75         The United States (US) is considered a susceptible region with great potential for JEV  
76 introduction. The availability of competent vectors, susceptible maintenance hosts (avian),  
77 intensive travel and trade activities to and from JEV-affected countries, areas with similar  
78 climatic and environmental conditions to countries where the virus is epidemic, and large  
79 populations of susceptible, amplifying hosts (domestic and feral pigs), makes the US the perfect  
80 next-stop in the JEV travel itinerary. In fact, the US is the world's third-largest producer and  
81 consumer of pork and pork products (USDA - ERS). The size of the swine industry in the US  
82 can not only be positively correlated with the ability of this virus to invade and establish itself,  
83 but also to the impact that an incursion would cause to the economy and the populations' health.  
84 As pigs are considered the main amplifying host of JEV, an extensive review of the literature and  
85 identification of knowledge gaps may guide researchers, stakeholders, and policy makers on  
86 effort prioritization, development of precautionary intervention measures (to prevent JEV  
87 introduction), and evaluation of disease control measures (in case of JEV incursion). Although  
88 current conditions have not been favorable for JEV to establish in the US, increases in  
89 international trade and globalization, as well as changes in climate and land use, and reductions  
90 in pesticide use, can contribute to its rapid and wide geographical spread (Oliveira et al., 2018).  
91 A good understanding of the role of swine as an amplifying host for this virus is critical to public  
92 health authorities when planning and executing interventions to control the spread of JEV.

93 Therefore, our objectives are 1) to investigate the role of swine on the risk of JEV transmission  
94 in the US as an effort for preparedness in the case of an introduction, and 2) to identify  
95 knowledge gaps that may serve as a guide to future research efforts.

96

## 97 **Objectives**

98 The objectives of this review are: 1) to gather and summarize available scientific  
99 literature on the role of swine (with emphasis on the role of feral swine) in the transmission of  
100 the JEV and 2) to identify knowledge gaps and potential areas amenable for future research,  
101 focusing on the role of swine (domestic and feral) in the transmission of the JEV.

102 Therefore, this rapid review will address the following questions as they are related to  
103 both domestic and feral pigs: 1) What is the role of swine in the transmission of JEV?; 2) What is  
104 the JEV seroprevalence in pigs (domestic and feral)?; 3) Are there differences in JEV  
105 transmission depending on the type of swine operations (confined commercial or research vs.  
106 opened commercial or research vs. semi-opened commercial or research vs. subsistence  
107 farming)?; 4) Are there differences in JEV transmission depending on the size of the swine  
108 operations?; 5) Are there differences in JEV transmission depending on the location of the swine  
109 operations (urban vs peri-urban vs rural; proximity to bodies of water)?; 6) What are the most  
110 important routes of infection/transmission in swine?; 7) Are there differences in swine  
111 transmission and/or pathophysiology among JEV genotypes (including differences in  
112 infectiousness, lesions, clinical signs)?; 8) Are there management or biosecurity/hygiene  
113 procedures that are associated with susceptibility of JEV introduction/transmission (e.g.,  
114 quarantine, segregation, personnel standard procedures, animal-sourcing, truck trafficking  
115 procedures, testing, mosquito trapping, in-house surveillance/testing)?; 9) What surveillance

116 efforts have been put in place worldwide (e.g., use of bird or pig sentinels, mosquito trapping)?;

117 10) What is the speed by which JEV spreads within a population (reproductive number/ratio ( $R_0$ )

118 for JEV); 11) What have been the most successful preparedness response strategies (vaccine

119 banks, diagnostic tests, trained veterinarians, other strategic measures that allow a quick

120 response) deployed in other countries for reducing JEV prevalence/transmission?; 12) Are there

121 differences among pig breeds/genetic makeup that are known to influence swine herd

122 susceptibility to JEV transmission?; 13) Is there a difference in JEV susceptibility based on the

123 sex and/or age category of pigs?; 14) Regarding immunization status (to other viruses besides

124 JEV), is there any cross-protection with other viruses?; 15) Which JEV vaccines are available for

125 use in swine?; 16) What vaccines are the most effective for swine?; 17) What is the

126 sensitivity/specificity of diagnostic tests available for detection of JEV in swine?; 18) Can JEV

127 be found/transmitted/introduced via pork products?

128

## 129 **Registration and amendments**

130 This protocol has been drafted, using the Preferred Reporting Items for Systematic

131 Reviews and Meta-analysis Protocols (PRISMA-P). This protocol will be made publicly

132 available within the K-Rex database ([K-Rex/CORE collection](#)). *Post hoc* changes made to the

133 protocol will be recorded and posted as an updated version in the same database. Any changes in

134 the original protocol will be accompanied by a footnote indicating the date of change, and the

135 rationale. Added content will be displayed with an underline and deleted text will be shown with

136 a strike through.

137

## 138 **Eligibility criteria**

139 For the “primary” search, the sources of evidence must include peer-reviewed papers,  
 140 written in English, and containing information regarding the role of domestic and feral swine in  
 141 the transmission of JEV. For the “grey literature” search, the sources of evidence may or may not  
 142 be peer-reviewed, but must be in English, and include information regarding the role of feral  
 143 swine in the transmission of JEV. We will use a POS (Population Outcome Study design)  
 144 framework for both primary and grey literature searches with no time restrictions, as depicted in  
 145 Table 1 and Table 2, respectively.  
 146

**Table 1.** Eligibility criteria for the **primary database search** (does not include grey literature search)

<b>Population (P)</b>	Swine (domestic ( <i>Sus domesticus</i> ) and feral ( <i>Sus scrofa</i> )) of all ages, sexes, and breeds
<b>Outcome (O)</b>	Transmission efficiency, infectiousness, susceptibility to infection, incubation time, duration of viremia, routes of transmission, physiopathology, economic/productivity (reproductive) impacts, vaccine efficacy, diagnostic test performance, pathogen/genotype characteristics (pathogenicity, virulence, infectivity, etc.), among others.
<b>Study design (S)</b>	No restriction.
<b>Language</b>	English
<b>Location</b>	No restriction
<b>Time period</b>	No restriction
<b>Type of evidence</b>	Peer-reviewed articles, and government reports

**Table 2.** Eligibility criteria for the **grey literature** search

<b>Population (P)</b>	Feral swine ( <i>Sus scrofa</i> ) of all ages, sexes, and breeds
<b>Outcome (O)</b>	Transmission efficiency, infectiousness, susceptibility to infection, incubation time, duration of viremia, routes of transmission, physiopathology, economic/productivity (reproductive) impacts, vaccine efficacy, diagnostic test performance, pathogen/genotype characteristics (pathogenicity, virulence, infectivity, etc.), among others.
<b>Study design (S)</b>	No restriction.
<b>Language</b>	English
<b>Location</b>	No restriction
<b>Time period</b>	No restriction
<b>Type of evidence<sup>‡</sup></b>	Theses, technical reports, APHIS reports

148 <sup>‡</sup>Include articles by Vienna Brown, USDA National Wildlife Research Center  
 149 (<https://www.aphis.usda.gov/aphis/ourfocus/wildlifedamage/programs/nwrc>), and USDA  
 150 Current Research Information System (CRIS; <https://cris.nifa.usda.gov/>).

151  
 152 The following rapid review (RR) approaches will be incorporated to expedite the  
 153 eligibility assessment of the studies: 1) Limit the number of outcomes focusing on those most  
 154 important for decision-making (outcomes of interest will be defined based on stakeholder group  
 155 interests) (Garrity et al., 2021), 2) Limit inclusion criteria to English language only publications  
 156 (Nussbaumer-Streit et al., 2020). Nussbaumer-Streit et al. (2020) reported that this approach had



157 minimal effect on overall conclusions when applied on clinical interventions; however, the  
158 authors advise to consider the subject carefully (i.e., topics that are expected to have relevant  
159 literature in other languages beside the chosen one).

160

### 161 **Information sources**

162 Identification of potentially relevant literature will be performed using the databases  
163 described in Table 3.

**Table 3.** Databases, interface used, and dates encompassed for the rapid review

Database	Interface	Dates included
Web of Science Core Collection; KCI-Korean Journal Database; MEDLINE; SciELO Citation Index	Web of Science	1950 - 2022
Scopus	Scopus, Elsevier	1920 - 2022

164

165 The following RR approaches will be incorporated to expedite the identification of  
166 relevant literature: 1) Limit the number of electronic databases searched (Garrity et al., 2021).  
167 Nussbaumer-Streit et al. (2020) evaluated the effect of various abbreviated search approaches on  
168 the overall conclusions of evidence synthesis and concluded that combining at least one  
169 electronic database with a search of reference lists or a second database provides a solid base for  
170 decision-making in most cases. MEDLINE was the only exception where the combination with  
171 reference lists was not sufficient. 2) Hand searching only reference lists that were deemed  
172 relevant by reviewers and after consultation with experts (Royle and Waugh, 2003). Royle and  
173 Waugh (2003) concluded that a more selective approach to database searching is a viable  
174 approach to expedite reviews and save resources.

175 Before defining the primary databases and based on recommendations from Garrity et al.  
176 (2021), we performed a pilot search using WOS, Scopus, and CAB to evaluate the total number  
177 of references yielded with the proposed search strategy (described in the Search strategy section)  
178 in each database, the overlapping of results among those 3 databases (WOS, Scopus, and CAB),  
179 and the relevance of results. The two selected databases were the ones with less overlap, that  
180 yielded a great number of relevant references.

181

## 182 **Search strategy**

183 Primary databases (Table 4) searches will be performed by one reviewer (VV), using the  
184 following search terms: “Japanese encephalitis”, “Japanese B encephalitis”, “viral encephalitis”,  
185 “JE”, “JEV”, “summer encephalitis”, “viral meningitis”, “Russian autumnal encephalitis”,  
186 “swine”, “pork”, “sow”, “gilt”, “piglet”, “barrow”, “hog”, “pig”, “boar”, “*Sus domesticus*”, and  
187 “*Sus scrofa*”.

188 A grey literature search will be conducted based on expert guidance to address the role of  
189 swine, but specifically feral swine, in the transmission of JEV. The grey literature search will be  
190 specified based on the filtering allowances of each database, but guided by the following search  
191 terms: “Japanese encephalitis”, “Japanese b encephalitis”, “JEV”, “JE”, “summer encephalitis”,  
192 “viral encephalitis”, “viral meningitis”, “Russian autumnal encephalitis”, “swine”, “boar”,  
193 “hog”, “pig”, “pork”, “sow”, “gilt”, “piglet”, “barrow”, “wild”, “feral”, “game”, “free range”,  
194 “ranging”, “free-roaming”, “sus scrofa”, “undomesticated”, and “non-domesticated”. Tables 4  
195 and 5 describe results obtained from specific search strategies implemented in Web of Science  
196 (WOS) and Scopus, and when searching grey literature (respectively).

197

198 **Table 4.** Results obtained from Web of Science (WOS) and Scopus using the search strategy, and different  
 199 combinations, on August 09, 2022

Database <sup>§</sup>	Keyword search	Results
WOS	3: #1 AND #2  2: ((((((((((TS=(swine)) OR TS=(pig)) OR TS=(hog)) OR TS=(boar)) OR TS=(pork)) OR TS=("sus scrofa")) OR TS=("sus domesticus")) OR TS=(barrow)) OR TS=(gilt)) OR TS=(piglet)) OR TS=(sow)  1: (((((((TS= ("Japanese encephalitis")) OR TS= ("Japanese b encephalitis")) OR TS=(JEV)) OR TS=(JE)) OR TS= ("summer encephalitis")) OR TS= ("viral encephalitis")) OR TS= ("viral meningitis")) OR TS= ("Russian autumnal encephalitis"))	618
Scopus	TITLE-ABS-KEY ("Japanese encephalitis" OR "Japanese b encephalitis" OR "JEV" OR "je" OR "summer encephalitis" OR "viral encephalitis" OR "viral meningitis" OR "Russian autumnal encephalitis" OR "viral encephalitis") AND (swine OR boar OR hog OR pig OR pork OR "sus scrofa" OR "sus domesticus" OR sow OR piglet OR gilt OR barrow)	2,545

200 <sup>§</sup> TS = Search for topic terms in the following fields within a record. Search in title, abstract,  
 201 author keywords, and keywords Plus®. TITLE-ABS-KEY = Search for topic terms in the title,  
 202 abstract, and keywords.

203

**Table 5.** Results obtained from grey literature and hand search, in August 2022.

Database	Keyword search	Results <sup>0</sup>
USDA Animal and Plant Health Inspection Service (APHIS) <sup>1</sup>	"Feral swine" "Japanese encephalitis"	1881
Center for Disease Control and Prevention (CDC) <sup>2</sup>	ALL THIS WORD: Japanese encephalitis ANY OF THESE WORDS: feral wild undomesticated free-range ranging roaming swine pig hog boar pork	7266
USDA National Wildlife Research Center <sup>3</sup>	6: "japanese encephalitis" AND feral AND boar (n = 2) 5: "japanese encephalitis" AND wild AND boar (n = 2) 4: "japanese encephalitis" AND feral AND pig (n = 1) 3: "japanese encephalitis" AND wild AND pig (n = 4) 2: "japanese encephalitis" AND wild AND swine (n = 7) 1: "japanese encephalitis" AND feral AND swine (n = 7)	330
USDA Current Research Information System (CRIS) <sup>4</sup>	"Japanese encephalitis" AND (feral; wild; "free range"; ranging; "free roaming"; game; undomesticated) AND (swine; pig; boar; hog; pork; "sus scrofa")	1249
Articles by Vienna Brown <sup>5</sup>	("Japanese encephalitis", "Japanese b encephalitis", "JEV", "JE", "summer encephalitis", "viral encephalitis", "viral meningitis", "Russian autumnal encephalitis", "viral encephalitis") OR (("swine", "boar", "hog", "pig", "pork")	33

AND (“wild”, “feral”, “game”, “free range”, “ranging”, “free roaming”, “sus scrofa”, and “undomesticated”))

Reference lists of (“Japanese encephalitis”, “Japanese b encephalitis”, “JEV”, 92  
Wildlife Health “JE”, “summer encephalitis”, “viral encephalitis”, “viral  
Australia<sup>6</sup> meningitis”, “Russian autumnal encephalitis”, “viral  
encephalitis”) OR ((“swine”, “boar”, “hog”, “pig”, “pork”) AND (“wild”, “feral”, “game”, “free range”, “ranging”, “free roaming”, “sus scrofa”, and “undomesticated”))

---

<sup>0</sup> Resulting number for each source is reported before de-duplication of references

<sup>1</sup> Keyword search will be conducted within each database, using the website search option.

<https://www.aphis.usda.gov/aphis/home/>

<sup>2</sup> Search was performed using the “advanced search” option-fields

<sup>3</sup> Wildlife Services Digital Collection

(<https://nwrc.contentdm.oclc.org/digital/collection/NWRC PUBS1>); the wild-synonyms “game”, “free range”, “ranging”, “free-roaming”, “undomesticated”, and “non-domesticated” did not find any result.

<sup>4</sup> Search term string was entered in “Full text Terms” field-option, using “Subfile option” as “(Any)”. <https://cris.nifa.usda.gov/cgi-bin/starfinder/99451/crisassist.txt>

<sup>5</sup> Articles by Vienna Brown include: 1) Brown VR, Bowen RA, Bosco-Lauth AM. Zoonotic pathogens from feral swine that pose a significant threat to public health. *Transbound Emerg Dis.* 2018 Jun;65(3):649-659. 2) Brown, Vienna R., et al. Current status and future recommendations for feral swine disease surveillance in the United States. *Journal of Animal science* 97.6 (2019): 2279-2282. 3) Brown, Vienna R., et al. Perspectives on the past, present,

and future of feral swine disease surveillance in the United States. *Journal of Animal Science* 98.8 (2020): skaa256.

<sup>6</sup>The reference list of the review article was searched for titles referring to Japanese encephalitis in wild pigs and all above mentioned synonyms.

---

204

## 205 **Data management**

206 A single reviewer (VV) will export results from the databases as Research Information  
207 Systems (RIS) files and deduplicate the reference list using Covidence AI (Covidence systematic  
208 review software, Veritas Health Innovation, Melbourne, Australia). Following relevance  
209 screening, full-text pdfs from relevant reference lists will be searched, downloaded, and saved in  
210 a single folder by an undergraduate student-worker (ME). Full-text pdf files will be named based  
211 on the first Covidence ID number, author's last name, and publication year (first authors having  
212 multiple publications in the same year will have the year followed by a unique letter (e.g., 764 -  
213 Sympson 2020; 765 - Sympson 2022)). Full-text pdfs will be imported into Zotero (Corporation  
214 for Digital Scholarship, Virginia, USA), and then uploaded into Covidence using the bulk upload  
215 function (VV).

216

## 217 **Relevance Screening/Selection process**

218 The selection process of the primary databases (Table 4) will be performed according to  
219 the following steps:

220 #1: Citation retrieval. Citations from the search strategy will be downloaded as RIS and  
221 then uploaded into Covidence as described on the data management section.

222 #2: Deduplication. Duplicated references will be removed using Covidence's  
223 deduplication tool.

224 #3: Primary relevance screening tool development. A screening tool comprised of a flow  
225 chart will be designed based on the POS and the current study objectives. The tool will be piloted  
226 using 150 random abstracts (sorted by author in Covidence) and adjusted/edited if necessary to  
227 improve clarification of the relevance criteria. If major edits were incorporated, an additional  
228 round of screening will be performed in another set of 50 random abstracts. This process will be  
229 repeated until clarity of relevance criteria is deemed sufficient by the reviewers (VV and CH).  
230 Once the relevance screening tool is finalized, all articles will be screened using the same, final,  
231 screening tool.

232 #4: Primary relevance screening tool calibration. The proposed primary relevance  
233 screening tool will be tested for clarity and utility. For the test exercise, a pair of reviewers (VV  
234 and CH) will independently review a random sample of 20% of the total titles and abstracts and  
235 assess eligibility. Reviewers will compare their results and discuss any differing decisions or  
236 questions that arose during the screening. The primary relevance screening tool will be used in  
237 its current form only if >80% agreement is achieved between reviewers. If this threshold is not  
238 met, then the primary relevance screening tool will be amended based on reviewer  
239 recommendations, and another iteration of screening will be performed to another set of 25  
240 citations; this process will continue until at least 80% agreement is achieved.

241 #5: Title and Abstract screening. Once a final version of the relevance screening tool is  
242 decided upon, VV and CH will complete the title and abstract screening. During this step, one  
243 reviewer will evaluate each reference (VV) and a second reviewer will check excluded  
244 references for inconsistencies (CH). Articles deemed unclear by the primary reviewer will be re-

245 evaluated by the second reviewer (CH). Only articles deemed unclear by both reviewers during  
246 the primary screening will undergo a supplementary screening (full text screening).  
247 Disagreements between the primary and verifier reviewer on excluded and unclear articles will  
248 be indicated by the verifier with a note explaining the reason for disagreement. Disagreements  
249 will be resolved via consensus between the two reviewers (VV and CH). If consensus cannot be  
250 achieved, then a third reviewer (NC) will be consulted. Supplementary screening will be  
251 performed by the verifier reviewer (CH) using the full text article and the same relevance tool as  
252 the primary screening. Studies included in the primary relevance screening will move directly to  
253 data extraction, as well as those deemed unclear during the first relevance screening and  
254 subsequently identified as relevant after the supplementary relevance screening. References that  
255 moved to the supplementary screening phase or extraction phase can still be excluded if deemed  
256 not relevant. References excluded during the supplementary screening or extraction phase will  
257 receive a tag with the reason for exclusion.

258           Non-peer-reviewed articles on JEV and feral swine will be excluded from primary  
259 relevance screening with a “grey literature” tag. Excluded references containing “grey literature”  
260 tags will be evaluated using the grey literature relevance screening process.

261           The selection process of the grey literature and hand search (Table 5) will be performed  
262 according to the following steps:

263           #1: A search strategy will be defined according to each electronic source based on search  
264 resources/restrictions available in each electronic database.

265           #2: Results obtained from each combination of words in each database will be screenshot  
266 and saved as a record of search terms used and resulting references obtained.



267 #3: The relevance screening of grey literature (i.e., governmental organizations  
268 databases) and hand search (i.e., reference list of reference review articles) will be performed by  
269 accessing the relevance of titles first. Only titles that include either JEV (or synonymous), or  
270 wild swine (or synonyms) will be further investigated for relevance, using the full text file.

271 #4: Relevant literature will be downloaded and included for data extraction.

## 272 **Data extraction**

273 Data extraction will be performed in ~~Covidence-Excel~~ (changed due to the complexity of the data being  
274 extracted and Covidence's capacity to extract several outcomes per reference | 11.20.23), using a custom-built data collection  
275 form. Data extraction form will be assessed with a calibration exercise, similar to the one  
276 performed for the relevance screening tool. After achieving 80% agreement during the  
277 calibration exercise, and upon refinement of the data extraction tool, full-text articles will be  
278 evaluated for extraction in duplicate by two reviewers (VV and CH) independently. Unresolved  
279 discrepancies will be resolved by a third reviewer (NC). Full-text articles can still be excluded  
280 during the data extraction process (if deemed irrelevant during extraction phase). Exclusion of  
281 studies that moved to the extraction phase will be performed by moving the study back to  
282 screening when choosing the Covidence built-in option "Move study to Full text review", then  
283 the article will be double-tagged with a 1) reason for exclusion, and 2) "retracted-during-  
284 extraction" tags. The following RR approaches will be incorporated to expedite data extraction:  
285 1) Limit data extraction to a minimal set of required data items, and limit the outcomes to cost-  
286 effectiveness (Tricco et al., 2015); 2) Use standardized data extraction form piloted elsewhere  
287 (Wollscheid and Tripney, 2021); 3) Use data from existing SR to reduce time spent on data  
288 extraction; however, the methodological and reporting quality of the existing SR will be assessed  
289 (Hamel et al., 2020; Martyn-St James et al., 2017). When comparing the accuracy of extracting

290 data from an existing SR versus extracting from the primary studies, Martyn-St James et al.  
 291 (2017) concluded that data in existing reviews were highly accurate, and findings and  
 292 conclusions did not differ between methods.

293

294 **Data items**

295 All variables for which data will be sought will be defined (such as POS items, funding  
 296 sources, location), including prioritization of main and additional outcomes (with rationale), any  
 297 pre-planned data assumptions and simplifications (Table 6). Experts and/or stakeholders in the  
 298 topic area will be involved in early stages of the project to ensure the included outcomes are  
 299 relevant.

**Table 6.** List of data items that will be extracted from the included reference list of studies

<b>Data item*</b>	<b>Explanation</b>
Reference information	Title, all authors, first affiliation, journal, volume, pages, and publication date
Type of evidence	Peer-reviewed or not
Type of evidence – peer-reviewed	Primary research (original papers), review, systematic review, N/A
Type of evidence – non-peer-reviewed	Theses, technical reports, other, N/A
Quality of systematic reviews/scoping reviews	Was there an assessment of the quality of evidence (RoB or GRADE)?
<b>Study characteristics</b>	
Year and season of study	Year and season when the study was conducted, or not reported (NR)

Country and region	Country and region where the study was conducted. If not reported, reviewers will report the main author's institution location.
Study type	Reported study design as review, experimental or observational, or not reported (NR)
Study design – observational: type	Reported study design as case-control, cohort, cross-sectional, other
Study design - experimental: type	Reported study design as RCBD, CRD, split-plot, cross-over, latin-square, ND (used in studies with no design/randomization), or NR
Study design – experimental: randomization method (if RCBD or CRD)	If the study design is reported as RCBD, then reported randomization method used for the study, or N/A (if not a randomized study), or NR
Study design - experimental: type of exposure	Reported type: laboratory natural, field natural , Lab challenge, Field challenge, or not reported (NR)
Study design - experimental: preventive intervention	Vaccine, quarantine, mosquito-control, testing of new animals, segregation, sanitation, NR, or N/A
Study design - experimental: curative intervention	Management of positive animals (segregation, euthanasia and disposal, other) disposal of contaminated material (placenta, stillborn piglets), treatment of positive animals, NR, N/A
Study design – experimental: treatment structure	Reported treatment structure as one-, two-, three-way factorial, or NR

Total number of EU	Number of experimental units (unit of replication) used in the study, or NR
Number of EU/treatments	Number of EU per treatment (replication), or NR
Blinding	Was the use of blinding reported? Single-blind, double-blind, triple-blind, no, or unclear
Blinding: level	Data collectors, data collectors & data analyst, NR
Confounding	Is confounding addressed and accounted for? Yes, No, or Unclear
Sample size determination	Is there a sample size determination conducted? (this will address the “imprecision” domain of quality of evidence (to add in discussion section). Yes, No, or Unclear
<b>Outcomes</b>	
JEV case definition	Method used to confirm disease (diagnostic test, clinical signs, other, NR)
JEV case definition: diagnostic test	What diagnostic test was used (ELISA, HIA (hemagglutination inhibition assay) HIA+SNT (seroneutralization test), PCR, RT-PCR, other, NR or N/A
JEV case definition: clinical signs	Combination of clinical signs used to declare as positive JE case, NR or N/A

JEV seroprevalence	Reported prevalence (% , proportion, measures of association, etc.) and test used for prevalence determination; NR, or N/A
JEV morbidity (prevalence based on clinical signs)	%, proportion, etc; NR, or N/A
Infection rate in swine	Infection rate (also known as “R(t)”) is the estimated number of new swine that become infected during a specific time period; NR, or N/A
Incubation period in swine	The number of days between infection and manifestation of clinical signs; NR, or N/A
Routes of transmission in swine	The pathway through which JEV enters the organism to infect a susceptible host; NR, or N/A
Pathological lesions in swine	Anatomical changes caused by the pathological agent during course of disease; NR, or N/A
Clinical signs in swine	Signs associated with the manifestation of disease; NR, or N/A
Swine demographics	Sex, age, breed, and genetic markers; NR, or N/A
JEV immunization status of swine herd	What JEV vaccines were administered to the herd? Commercial name, doses, route of administration; NR, or N/A
Production size	One time capacity of the entire farm, NR, or N/A.
Barn size	Total number of animals per barn, NR, or N/A

Pen size	no of animals/pen, NR, or N/A
Farm location	Urban, peri-urban, rural, NR, or N/A (as reported by the authors)
Type of operation	Type of swine operations will be described as: confined commercial or research; opened commercial or research; semi-opened commercial or research; or subsistence farming (“backyard pigs”), NR, or N/A
Type of production	Farrow to finish, farrow to wean, feeder pig production, wean to finish, seedstock production, or purebred production, NR, or N/A
Production system	Conventional or alternative/organic (antibiotic-free, and hormone-free raised pigs, other), NR, or N/A
Biosecurity/hygiene procedures applied at the farm (in general and specific to JEV)	Quarantine, segregation, personnel standard procedures, animal-sourcing, conveyance management , testing, mosquito control, in-house surveillance/testing, NR, or N/A
Effectiveness of farm biosecurity measures	Include measure of effectiveness, NR, or N/A
JEV surveillance strategies	Mosquito trapping, use of sentinels, etc.; NR, or N/A
Effectiveness of surveillance	Critical evaluation of the effectiveness of JEV surveillance programs used to detect and monitor JEV in endemic regions; NR, or N/A
Genotype	I, II, II, IV or V; NR, or N/A

R0	Reproductive number; estimate of JEV contagiousness; NR, or N/A
Vaccine efficacy/effectiveness	Degree to which a vaccine prevents disease; NR, or N/A
Type of diagnostic test	Type (antibody, antigen, etc.), name; NR, or N/A
Diagnostic test performance	Sensitivity, specificity, likelihood ratios, predictive values, and/or other accuracy measures reported for a diagnostic test; NR, or N/A

\*RCBD = randomized complete block design; EU = experimental unit; JEV = Japanese encephalitis virus; R0 = R-naught

300

### 301 **Risk of bias assessment (RoB)**

302           Upon determining all relevant articles, an independent reviewer (NC) will evaluate the  
303 risk of bias for these articles and document the results. A second reviewer will be available to  
304 discuss uncertainties brought up by the primary reviewer. This step will be implemented  
305 concurrently with the initiation of the data extraction step. To accelerate this process, we will  
306 implement the RR approaches suggested by Garrity et al. (2021) when conducting the RoB  
307 rating, which include: 1) limit RoB assessment to only primary outcomes, and 2) use a valid RoB  
308 assessment tool specific to the study designs included (<https://www.riskofbias.info>).

309

### 310 **Data synthesis**

311           Methods for summarizing the data around the POS question framework elements with  
312 findings grouped by key questions, population of interest, and outcomes, will be implemented.  
313 We will use a combination of 1) minimal evidence synthesis (described by Haby et al. (2016) as  
314 “a locally prepared, short, contextually framed, narrative report in which the results of the

315 systematic review were described and locally relevant factors that could influence the  
316 implementation of evidence-based guideline recommendations were highlighted”), and 2) tabular  
317 synthesis of data (for narrative and quantitative data syntheses).

318

### 319 **Identification and characterization of knowledge gaps**

320 We will use a framework (Figure 1; Robinson et al., 2013) developed to systematically  
321 identify research gaps from systematic reviews. This framework facilitates the classification of  
322 where and why the current evidence falls short and includes two elements: (1) characterization of  
323 the gaps and (2) the identification and classification of the reason(s) for the research gap  
324 (Robinson et al., 2013).

325 The PICOS (in our case POS) structure can be used to describe questions or parts of  
326 questions inadequately addressed by the evidence synthesized in the RR. The second element of  
327 the framework consists of classifying the reasons behind a research gap. For each research gap  
328 (row of the worksheet: “Serial no.”), the reason(s) that most preclude conclusions from being  
329 made in the RR will be chosen by the reviewer completing the framework. Reasons for research  
330 gaps will be categorized as per Robinson et al. (2013): A. Insufficient or imprecise information,  
331 B. Biased information, C. Inconsistent or unknown consistency, and D. Not the right information  
332 (See Figure 1 footnote). Insufficient information (A) will be used when only a limited number of  
333 studies or none are identified, or if the sample sizes in the available studies are too small to allow  
334 conclusions. Biased information (B) will be concluded based of the aggregate risk of bias  
335 (dependent on risk of bias of the individual studies). Consistency (C) will be evaluated based on  
336 the effect size directionality of included studies (i.e., inconsistency will be attributed to a  
337 research gap when the reported effect sizes of included studies appear to go in opposite  
338 directions). Lastly, lack of right information (D) will be assigned to research gaps which result  
339 from included studies that are not applicable (e.g., different population, different research  
340 setting), do not include/report outcomes of interest for the review, whose duration of study  
341 period is insufficient, or other reasons that may be categorized as "D".



342 In the worksheet table, the person conducting the identification and characterization of  
 343 the knowledge gap (VV and CH) should identify the project name, date of completion,  
 344 worksheet page number (out of total number of pages), and the key question number. Christy  
 345 Hanthorn and VV will work concurrently in the knowledge gaps, each addressing a different  
 346 research gap (i.e., this step will not be conducted in duplicate).

347

348 **Figure 1. JHU EPC Frameworks Project: Research Gaps Worksheet and Instructions**  
 349 **(Original)<sup>+</sup>**

350 <Example Project Name>

Completed by – V. Veloso

351 **Research Gap Worksheet**

Date – 08.10.22

352 Page 1 of 1

353 **Key Question – 2** (What is the JEV seroprevalence in pigs (domestic and feral?)

Serial no.	Reason(s) for gap*	Population (P)	Intervention (I)	Comparison (C)	Outcomes (O)	Setting (S)	Free text of gap	Notes
Ex. 1	B1	Domestic pigs (sow)			seroprevalence	-		Study used wrong diagnostic test
Ex. 2	D1, D4	Feral swine in the US	-	-	-			
Ex 3	A3	Domestic pigs (barrow)			seroprevalence			

354 \*Reasons for Gap: A) **Insufficient or Imprecise Information** -> **A1**=No studies, **A2**=Limited number of studies,

355 **A3**=Sample sizes too small, **A4**=Estimate of effect is imprecise

356 B) **Biased Information** -> **B1**=Inappropriate study design, **B2**=Major methodological limitations in studies

357 C) **Inconsistency or Unknown Consistency** -> **C1**=Consistency unknown (only 1 study), **C2**=Inconsistent results  
 358 across studies

359 D) **Not the right information** -> **D1**=Results not applicable to population of interest, **D2**=Inadequate duration of

360 interventions/comparisons, **D3**=Inadequate duration of follow-up, **D4**=Optimal/most important outcomes not

361 addressed, **D5**=Results not applicable to setting of interest

362 †([https://www.ncbi.nlm.nih.gov/books/NBK126708/pdf/Bookshelf\\_NBK126708.pdf](https://www.ncbi.nlm.nih.gov/books/NBK126708/pdf/Bookshelf_NBK126708.pdf))

363

364 **Meta-biases (for systematic reviews):** Meta-bias will not be implemented in this RR.

365

366

367 **References**

368 Campbell G.L., Hills S.L., Fischer M., et al. Estimated global incidence of Japanese encephalitis:  
369 a systematic review. *Bull World Health Organ* 2011; 89:766–74.

370 <https://doi.org/10.2471/BLT.10.085233>

371

372 Fischer, M., Hills, S., Lindsey, N. and Staples, J.E., 2010. Japanese encephalitis vaccines;  
373 recommendations of the Advisory Committee on Immunization Practices (ACIP).

374

375 Garritty C., Gartlehner G., Nussbaumer-Streit B., King V.J., Hamel C., Kamel C., Affengruber  
376 L., Stevens A. Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to  
377 conduct rapid reviews. *Journal of clinical epidemiology*. 2021 Feb 1; 130:13-22.

378

379 Haby, M.M., Chapman, E., Clark, R., Barreto, J., Reveiz, L. and Lavis, J.N., 2016. What are the  
380 best methodologies for rapid reviews of the research evidence for evidence-informed decision  
381 making in health policy and practice: a rapid review. *Health research policy and systems*, 14(1),  
382 pp.1-12.

383

384 Hamel C., Michaud A., Thuku M., Affengruber L., Skidmore B., Nussbaumer-Streit B., Stevens  
385 A., Garritty C. Few evaluative studies exist examining rapid review methodology across stages  
386 of conduct: a systematic scoping review. *Journal of Clinical Epidemiology*. 2020 Oct 1;126:131-  
387 40

388

389 Hills, Susan L., I. B. Weber, and Marc Fischer. "Japanese encephalitis." (2014): 1-43.

390

391 Hopewell S., Clarke M.J., Lefebvre C., Scherer R.W. Handsearching versus electronic searching  
392 to identify reports of randomized trials. *Cochrane Database of Systematic Reviews*. 2007(2).

393

394 Jayatilleke, K., 2020. Challenges in implementing surveillance tools of high-income countries  
395 (HICs) in low middle income countries (LMICs). *Current treatment options in infectious*  
396 *diseases*, 12(3), pp.191-201.

397

398 Le Flohic, G., Porphyre, V., Barbazan, P. and Gonzalez, J.P., 2013. Review of climate,  
399 landscape, and viral genetics as drivers of the Japanese encephalitis virus ecology. *PLoS*  
400 *neglected tropical diseases*, 7(9), p.e2208.

401

402 Martyn-St James M., Cooper K., Kaltenthaler E. Methods for a rapid systematic review and  
403 metaanalysis in evaluating selective serotonin reuptake inhibitors for premature ejaculation. *Evid*  
404 *Policy* 2017; 13(3):517e38.

405

406 Nussbaumer-Streit, B., Klerings, I., Dobrescu, A.I., Persad, E., Stevens, A., Garritty, C., Kamel,  
407 C., Affengruber, L., King, V.J. and Gartlehner, G., 2020. Excluding non-English publications  
408 from evidence-syntheses did not change conclusions: a meta-epidemiological study. *Journal of*  
409 *clinical epidemiology*, 118, pp.42-54.

410

411 Oliveira, A.R., Strathe, E., Etcheverry, L., Cohnstaedt, L.W., McVey, D.S., Piaggio, J. and  
412 Cernicchiaro, N., 2018. Assessment of data on vector and host competence for Japanese  
413 encephalitis virus: A systematic review of the literature. *Preventive veterinary medicine*, 154,  
414 pp.71-89.

415

416 Quan, T.M., Thao, T.T.N., Duy, N.M., Nhat, T.M. and Clapham, H., 2020. Estimates of the  
417 global burden of Japanese encephalitis and the impact of vaccination from 2000-2015. *Elife*, 9,  
418 p.e51027.

419

420 Robinson, K.A., Akinyede, O., Dutta, T., Sawin, V.I., Li, T., Spencer, M.R., Turkelson, C.M.  
421 and Weston, C., Framework for determining research gaps during systematic review: evaluation.  
422 2013.

423

424 Royle P., Waugh N. Literature searching for clinical and cost-effectiveness studies used in health  
425 technology assessment reports carried out for the National Institute for Clinical Excellence  
426 appraisal system. Health Technology Assessment (Winchester, England). 2003 Jan 1;7(34):iii-x.

427

428 Tricco, A.C., Antony, J., Zarin, W., Strifler, L., Ghassemi, M., Ivory, J., Perrier, L., Hutton, B.,  
429 Moher, D. and Straus, S.E., 2015. A scoping review of rapid review methods. BMC medicine,  
430 13(1), pp.1-15.

431

432 Wollscheid, S. and Tripney, J., 2021. Rapid Reviews as an Emerging Approach to Evidence  
433 Synthesis in Education. London Review of Education, 19(1), p.n1.

434

435 World Health Organization. Japanese encephalitis vaccines. Wkly Epidemiol Rec 2006; 81:331–  
436 40. PMID:16933380

437

438